Amicus Therapeutics, a Global Biotechnology Company

Amicus Therapeutics, incorporated in 2002, is a biopharmaceutical company located in New Jersey, in the United States. The company engages in the commercialization, development, and discovery of therapies that are advanced and used in orphan diseases and rare patients.

The company’s best product is Migalastat HCL, which is a molecule that is small used as a single drug or with ERT (enzymes for replacement therapy) as a combination therapy for genetic lysosomal storage disease that is rare and known as Fabry’s disease. Amicus Therapeutics investigates programs of discovery and preclinical in other rare diseases, including the deficiency of (STK9serine/threonine kinase 9).

The Michael Fox Foundation gave the company half a million US dollars as a grant, in 2010. The money was for supporting the studies carried out together with the David Geffen Medicine School at California University, Los Angeles.

In the same year, ADDF (Alzheimer’s Drug Discovery Foundation) also gave Amicus a grant to support their tests study; they conducted these test with Icahn Medicine

School, based in Mount Sinai, this was done through ADRC (Alzheimer’s Disease Research Center.)

John F. Crowley served Amicus Therapeutics as the Chief Executive Officer and Chairman before leaving the company, Bradley L. Campbell works for the company as the Chief Operating Officer and President, and Chip Baird serves the company as the Chief Financial Officer since 2012.

In 2013, the company acquired Callidus Biopharma and obtained the ownership and rights for the ERT (enzyme replacement therapy), a Pompe disease treatment.

Amicus Therapeutics is in Phase III clinical trials of SD-101, a topical medication used for treating Epidermolysis bullosa, a connective tissue disease. Also, it has started clinical trials in another Lysergic acid diethylamide in Pompe disease patients. The clinical trials investigate treating the disease using a drug that has ATB200. The drug administration will involve a combination with pharmacoperone.

Leave a Reply